These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25500799)

  • 1. Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials.
    Rangel MO; Morales Demori R; Voll ST; Wassouf M; Dick R; Doukky R
    J Nucl Cardiol; 2015 Oct; 22(5):1008-18. PubMed ID: 25500799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age and gender as predictors of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: a substudy of the ASSUAGE trial.
    Rangel MO; Demori RM; Doukky R
    Am J Ther; 2013; 20(6):622-9. PubMed ID: 24100259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial.
    Doukky R; Rangel MO; Dick R; Wassouf M; Alqaid A; Margeta B
    Int J Cardiovasc Imaging; 2013 Jun; 29(5):1029-37. PubMed ID: 23224354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial.
    Ballany W; Mansour K; Morales Demori R; Al-Amoodi M; Doukky R
    J Nucl Cardiol; 2014 Jun; 21(3):496-502. PubMed ID: 24519563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial".
    Doukky R; Morales Demori R; Jain S; Kiriakos R; Mwansa V; Calvin JE
    J Nucl Cardiol; 2012 Jun; 19(3):448-57. PubMed ID: 22395779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of a regimented aminophylline administration protocol on the burden of regadenoson-induced ischemia detected by SPECT myocardial perfusion imaging.
    Fughhi I; Campagnoli T; Ali A; Doukky R
    J Nucl Cardiol; 2017 Oct; 24(5):1571-1578. PubMed ID: 27233251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.
    Doukky R; Rangel MO; Wassouf M; Dick R; Alqaid A; Morales Demori R
    J Nucl Cardiol; 2013 Apr; 20(2):205-13. PubMed ID: 23239416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.
    Vij A; Golzar Y; Doukky R
    J Nucl Cardiol; 2018 Feb; 25(1):137-149. PubMed ID: 28653271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.
    Doukky R; Fughhi I; Campagnoli T; Wassouf M; Ali A
    J Nucl Cardiol; 2017 Feb; 24(1):112-118. PubMed ID: 26582040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease.
    AlJaroudi W; Campagnoli T; Fughhi I; Wassouf M; Ali A; Doukky R
    J Nucl Cardiol; 2016 Jun; 23(3):560-9. PubMed ID: 26293358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging.
    Amer KA; Hurren JR; Edwin SB; Cohen G
    Pharmacotherapy; 2017 Jun; 37(6):657-661. PubMed ID: 28475259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of hemodynamic and stress testing variables in patients undergoing regadenoson stress myocardial perfusion imaging to regadenoson with adjunctive low-level exercise myocardial perfusion imaging.
    Cabrera R; Husain Z; Palani G; Karthikeyan AS; Choudhry Z; Dhanalakota S; Peterson E; Ananthasubramaniam K
    J Nucl Cardiol; 2013 Jun; 20(3):336-43; quiz 344-5. PubMed ID: 23430361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis.
    Palani G; Husain Z; Salinas RC; Karthikeyan V; Karthikeyan AS; Ananthasubramaniam K
    J Nucl Cardiol; 2011 Aug; 18(4):605-11. PubMed ID: 21541818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
    Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminophylline and caffeine for reversal of adverse symptoms associated with regadenoson SPECT MPI.
    Doran JA; Sajjad W; Schneider MD; Gupta R; Mackin ML; Schwartz RG
    J Nucl Cardiol; 2017 Jun; 24(3):1062-1070. PubMed ID: 27025843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of regadenoson in patients with severe chronic obstructive pulmonary disease.
    Salgado-Garcia C; Jimenez-Heffernan A; Ramos-Font C; Lopez-Martin J; Sanchez-de-Mora E; Aroui T; Lopez-Aguilar R; Rivera-de-Los-Santos F; Ruiz-Frutos C
    Rev Esp Med Nucl Imagen Mol; 2016; 35(5):283-6. PubMed ID: 27160774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.
    Ananthasubramaniam K; Weiss R; McNutt B; Klauke B; Feaheny K; Bukofzer S
    J Nucl Cardiol; 2012 Apr; 19(2):319-29. PubMed ID: 22259009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson.
    Salgado-Garcia C; Jimenez-Heffernan A; Lopez-Martin J; Molina-Mora M; Aroui T; Sanchez de Mora E; Ramos-Font C; Rivera de Los Santos F; Ruiz-Frutos C
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1906-1914. PubMed ID: 28547175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.
    Partington SL; Lanka V; Hainer J; Blankstein R; Skali H; Forman DE; Di Carli MF; Dorbala S
    J Nucl Cardiol; 2012 Oct; 19(5):970-8. PubMed ID: 22565239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete heart block associated with regadenoson: a real side effect.
    Pandit A; Unzek Freiman S
    J Nucl Cardiol; 2012 Dec; 19(6):1236-9. PubMed ID: 22915132
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.